Sardeli Chrysanthi, Zarogoulidis Paul, Romanidis Konstantinos, Oikonomou Panagoula, Sapalidis Konstantinos, Huang Haidong, Bai Chong, Hohenforst-Schmidt Wolfgang, Tsakiridis Kosmas, Zaric Bojan, Perin Branislav, Ioannidis Aris, Baka Sofia, Drevelegas Konstantinos, Kosmidou Maria, Kosmidis Christoforos
Department of Pharmacology & Clinical Pharmacology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
3rd Department of Surgery, ''AHEPA'' University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece.
Respir Med Case Rep. 2020 Oct 25;31:101258. doi: 10.1016/j.rmcr.2020.101258. eCollection 2020.
Nowadays we have novel therapies for advanced stage non-small cell lung cancer. Immunotherapy has been introduced in the market for several years and until now its administration is mostly based on the programmed death-ligand 1. First line treatment with immunotherapy can be administered alone if programmed death-ligand 1 expression is ≥ 50%. All therapies for advanced stage disease have advantages and disadvantages, immunotherapy until now has presented mild adverse effects when compared to chemotherapy. However; it is known to induce inflammatory response to different tissues within the body. In our case acute pneumothorax was induced after immunotherapy administration.
如今，我们有针对晚期非小细胞肺癌的新型疗法。免疫疗法已投放市场数年，到目前为止，其应用主要基于程序性死亡配体1。如果程序性死亡配体1表达≥50%，一线免疫治疗可单独使用。所有晚期疾病的治疗方法都有优缺点，与化疗相比，免疫疗法目前表现出的不良反应较轻。然而，已知它会对体内不同组织引发炎症反应。在我们的病例中，免疫治疗后诱发了急性气胸。
